Imiquimod induces apoptosis of squamous cell carcinoma (SCC) cells via regulation of A20

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Sohn, Kyung Cheol ^a   Li, Zheng Jun ^a   Choi, Dae Kyoung ^a   Zhang, Tiejun ^a   Lim, Jae Woo ^a   Chang, In Kyu ^a   Hur, Gang Min ^a   Im, Myung ^a   Lee, Young ^a   Seo, Young Joon ^a   Lee, Jeung Hoon ^a   Kim, Chang Deok ^a  

^a Chungnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

A20 REGULATOR PROTEIN; IMIQUIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REGULATOR PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG; AMINOQUINOLINE DERIVATIVE; DNA BINDING PROTEIN; NUCLEAR PROTEIN; SIGNAL PEPTIDE; TLR7 PROTEIN, HUMAN; TNFAIP3 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; DRUG EFFECTS; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; TUMOR CELL LINE;

AMINOQUINOLINES; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DNA-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; NUCLEAR PROTEINS; TOLL-LIKE RECEPTOR 7;

EID: 84899744581     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095337     Document Type: Article

References (32)

1. Alam M, Ratner D (2001) Cutaneous squamous-cell carcinoma. N Engl J Med 344: 975-983. (Pubitemid 32240317)
2. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, et al. (1991) A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 88: 10124-10128. (Pubitemid 21915787)
3. Kolev V, Mandinova A, Guinea-Viniegra J, Hu B, Lefort K, et al. (2008) EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat Cell Biol 10: 902-911.
4. Zhao L, Li W, Marshall C, Griffin T, Hanson M, et al. (2009) Srcasm inhibits Fyn-induced cutaneous carcinogenesis with modulation of Notch1 and p53. Cancer Res 69: 9439-9447.
5. van Hogerlinden M, Rozell BL, Ahrlund-Richter L, Toftgard R (1999) Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kB signaling. Cancer Res 59: 3299-3303. (Pubitemid 29334479)
6. Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, et al. (2003) NF-kB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421: 639-643. (Pubitemid 36227672)
7. Stanley MA (2002) Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 27: 571-577.
8. Schiller M, Metze D, Luger TA, Grabbe S, Gunzer M (2006) Immune response modifiers-mode of action. Exp Dermatol 15: 331-341.
9. Bong AB, Bonnekoh B, Franke I, Schön M, Ulrich J, et al. (2002) Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology 205: 135-138.
10. Geisse JK, Rich P, Pandya A, Gross K, Andres K, et al. (2002) Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 47: 390-398.
11. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, et al. (2007) Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 204: 1441-1451. (Pubitemid 46919881)
12. Huang SJ, Hijnen D, Murphy GF, Kupper TS, Calarese AW, et al. (2009) Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol 129: 2676-2685.
13. Yokogawa M, Takaishi M, Nakajima K, Kamijima R, Digiovanni J, et al. (2013) Imiquimod attenuates the growth of UVB-Induced SCC in mice through Th1/Th17 cells. Mol Carcinog 52: 760-769.
14. Schön MP, Schön M, Klotz KN (2006) The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7-and TLR8-independent fashion. J Invest Dermatol 126: 1338-1347. (Pubitemid 43997917)
15. Lee JS, Kim DH, Choi DK, Kim CD, Ahn GB, et al. (2013) Comparison of Gene Expression Profiles between Keratinocytes, Melanocytes and Fibroblasts. Ann Dermatol 25: 36-45.
16. Shi G, Sohn KC, Li Z, Choi DK, Park YM, et al. (2013) Expression and functional role of Sox9 in human epidermal keratinocytes. PLoS One 8: e54355.
17. Won M, Park KA, Byun HS, Sohn KC, Kim YR, et al. (2010) Novel anti-apoptotic mechanism of A20 through targeting ASK1 to suppress TNF-induced JNK activation. Cell Death Differ 17: 1830-1841.
18. Li ZJ, Sohn KC, Choi DK, Shi G, Hong D, et al. (2013) Roles of TLR7 in activation of NF-kB signaling of keratinocytes by imiquimod. PLoS One 8: e77159.
19. Balkwill F, Coussens LM (2004) Cancer: an inflammatory link. Nature 431: 405-406. (Pubitemid 39329565)
20. Kobielak A, Fuchs E (2006) Links between a-catenin, NF-kB, and squamous cell carcinoma in skin. Proc Natl Acad Sci USA 103: 2322-2327. (Pubitemid 43271668)
21. Lee EG, Boone DL, Chai S, Libby SL, Chien M, et al. (2000) Failure to regulate TNF-induced NF-kB and cell death responses in A20-deficient mice. Science 289: 2350-2354.
22. Renner F, Schmitz ML (2009) Autoregulatory feedback loops terminating the NF-kB response. Trends Biochem Sci 34: 128-135.
23. Shembade N, Harhaj EW (2012) Regulation of NF-kB signaling by the A20 deubiquitinase. Cell Mol Immunol 9: 123-130.
24. Gilmore TD (2006) Introduction to NF-kB: players, pathways, perspectives. Oncogene 25: 6680-6684. (Pubitemid 44657845)
25. Baldwin AS Jr (1996) The NF-kB and IkB proteins: new discoveries and insights. Annu Rev Immunol 14: 649-683. (Pubitemid 26130197)
26. Garg A, Aggarwal BB (2002) Nuclear transcription factor-kB as a target for cancer drug development. Leukemia 16: 1053-1068. (Pubitemid 34618844)
27. Yu HG, Yu LL, Yang Y, Luo HS, Yu JP, et al. (2003) Increased expression of RelA/nuclear factor-kB protein correlates with colorectal tumorigenesis. Oncology 65: 37-45. (Pubitemid 36829089)
28. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, et al. (2003) Mitogenic and antiapoptotic role of constitutive NF-kB/Rel activity in pancreatic cancer. Int J Cancer 105: 735-746. (Pubitemid 36706095)
29. Li W, Tan D, Zenali MJ, Brown RE (2009) Constitutive activation of nuclear factor-kappa B (NF-kB) signaling pathway in fibrolamellar hepatocellular carcinoma. Int J Clin Exp Pathol 3: 238-243.
30. Seitz CS, Lin Q, Deng H, Khavari PA (1998) Alterations in NF-kB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kB. Proc Natl Acad Sci USA 95: 2307-2312. (Pubitemid 28145937)
31. Sakon S, Xue X, Takekawa M, Sasazuki T, Okazaki T, et al. (2003) NF-kB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J 22: 3898-3909. (Pubitemid 36975716)
32. Schön MP, Schön M, Klotz KN (2006) The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7-and TLR8-independent fashion. J Invest Dermatol 126: 1338-1347. (Pubitemid 43997917)